Kashiwagi, Hiroyuki <br/><br/>
Selective sigma-2 ligands preferentially bind to pancreatic adenocarcinomas: applications in diagnostic imaging and therapy.  [electronic resource] 

 -  Molecular cancer  Jul 2007 
 - 48 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-4598 
<br/><br/><label>Standard No.: </label>10.1186/1476-4598-6-48  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Animals<br/>Antineoplastic Agents--metabolism<br/>Apoptosis--drug effects<br/>Azabicyclo Compounds--metabolism<br/>Binding, Competitive<br/>Brain--cytology<br/>Carbamates--metabolism<br/>Caspase 3--metabolism<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Kidney--cytology<br/>Ligands<br/>Lung--cytology<br/>Mice<br/>Mice, Inbred C57BL<br/>Neoplasms, Experimental--drug therapy<br/>Pancreatic Neoplasms--drug therapy<br/>Positron-Emission Tomography<br/>Radioligand Assay<br/>Receptors, sigma--agonists<br/>Signal Transduction--drug effects<br/>Survival Analysis<br/>Tritium